January 5, 2015

Mylan announced the introduction of valsartan tablets USP in 40-, 80-, 160- and 320-mg dosage strengths. 

December 22, 2014

The Food and Drug Administration granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as detected by an FDA-approved test.

December 18, 2014

Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.

December 16, 2014

Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength. 


December 11, 2014

Teva Pharmaceuticals on Thursday announced the availability of levalbuterol inhalation solution, USP (concentrate), a generic equivalent to Xopenex inhalation solution concentrate. 

December 9, 2014

From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period. 

December 9, 2014

Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva. 

December 8, 2014

The pros of giving healthy women regular low dose aspirin to stave off such serious illness as cancer and heart disease are outweighed by the cons, suggests a large study published online last week in the journal Heart.

December 4, 2014

Camber Pharmaceuticals announced the addition of montelukast sodium tablets to its portfolio of products.

December 2, 2014

Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII.

December 1, 2014

NACDS advocated for the voluntary ability of pharmacies to extend their reward and loyalty programs to beneficiaries in government programs.

December 1, 2014

Teva Pharmaceutical on Monday announced the launch of a generic version of Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the United States. 

November 24, 2014

Dr. Reddy's Labs on Monday announced the launch of docetaxel injection USP in 20-mg and 80-mg dosage strengths. The drug is the generic version of Taxotere.


November 21, 2014

A study being published in Annals of Internal Medicine suggests that people with atrial fibrillation who take NSAIDs may be at risk for serious bleeding or thromboembolisms. 

November 20, 2014

Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.

November 13, 2014

 Janssen Pharmaceuticals announced that the Food and Drug Administration approved the company's supplemental new drug application for the once-monthly Invega Sustenna (paliperidone palmitate), an antipsychotic used to treat schizoaffective disorder as either monotherapy or adjunctive therapy. 

November 11, 2014

Teva Pharmaceuticals announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in a 5-mg strength.

November 10, 2014

Greenstone announced the launch of sirolimus tablets. The product is offered in 1-mg and 2-mg dosage strengths in bottles of 100 tablets each. 

November 10, 2014

Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application. 

October 31, 2014

Mylan on Friday announced the launch of nevirapine extended-release tablets in 400-mg strength, a generic version of Viramune XR from Boehringer Ingelheim. 

October 31, 2014

The signs for the retail clinic industry remain positive and conservative but steady growth in the number of clinics is expected to continue as drug stores play an essential role in the segment, according to new research from healthcare market researcher Kalorama Information.

October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 


October 17, 2014

Purdue Pharma has launched an awareness campaign to address specific knowledge gaps among pharmacists related to its Schedule III extended-release transdermal opioid, Butrans.

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday.